| Literature DB >> 32807200 |
Eline Lauwers1,2, Kris Ides3,4, Kim Van Hoorenbeeck3,4,5, Stijn Verhulst3,4,5.
Abstract
BACKGROUND: Airway clearance techniques (ACTs) are an important aspect of the treatment of children with chronic obstructive lung diseases. Unfortunately, a sound evidence base is lacking and airway clearance strategies are largely based on clinical expertise. One of the reasons for the limited evidence is the lack of appropriate outcome measures specifically related to the effectiveness of ACTs. This review discusses all outcome measures applied in previous research in the pediatric population to provide a baseline for future studies. DATA SOURCES: A systematic literature search was performed in PubMed, Web of Science and EMBASE databases. Search terms included chronic obstructive lung diseases and ACTs. STUDY SELECTION: Studies were independently selected by the investigators according to the eligibility criteria. After screening, 49 articles remained for further analysis. RESULTS ANDEntities:
Keywords: Airway clearance technique; Obstructive lung disease; Outcome measures; Pediatrics; Respiratory physiotherapy
Mesh:
Year: 2020 PMID: 32807200 PMCID: PMC7433087 DOI: 10.1186/s12931-020-01484-z
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1PRISMA flowchart study selection
Study characteristics
| Article | Design | Pathology | n | ACT | Duration | Type of outcome measures | LOE | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFT | SP | OX | EX | IM | DE | PRO | OTH | |||||||
| Denton 1962 [ | comparative | CF | 23 | CPT | 1x | • | • | 4 | ||||||
| Maxwell 1979 [ | RXO | CF | 14 | CPT | 1x | • | • | 2b | ||||||
| Weller 1980 [ | comparative | CF | 20 | CPT | 2x | • | • | 4 | ||||||
| Zach 1982 [ | comparative | CF | 10 | CPT, exercise | 17 d + 8 w | • | 4 | |||||||
| Desmond 1983 [ | RXO | CF | 10 | CPT | 3 w | • | • | 2b | ||||||
| De Boeck 1984 [ | RXO | CF | 9 | CPT | 1x | • | • | 2b | ||||||
| Andreasson 1987 [ | uncontrolled | CF | 7 | Exercise | 30 m | • | • | • | • | 4 | ||||
| Van Asperen 1987 [ | RXO | CF | 10 | CPT, PEP | 4 w | • | • | • | 2b | |||||
| Bain 1988 [ | RCT | CF | 38 (19/19) | CPT | 2 w | • | • | • | 2b | |||||
| Reisman 1988 [ | RCT | CF | 63 (30/33) | CPT, FET | 3 y | • | • | • | • | 1b | ||||
| Cerny 1989 [ | RCT | CF | 17 (8/9) | CPT, exercise | 13 d | • | • | • | 2b | |||||
| Maayan 1989 [ | RCT | CF | 25 (6/5/8/6) | CPT | 1x | • | 2b | |||||||
| Asher 1990 [ | RCT | Asthma | 38 (19/19) | CPT | 2 d | • | 1b | |||||||
| Oberwaldner 1991 [ | uncontrolled | CF | 18 | PEP | 16 d | • | 4 | |||||||
| Steen 1991 [ | RXO | CF | 28 | CPT, PEP, FET | 4 w | • | • | • | 1b | |||||
| Van der Schans 1991 [ | RXO | CF | 8 | PEP | 1x | • | • | 2b | ||||||
| Pfleger 1992 [ | RXO | CF | 14 | PEP, AD | 1x | • | • | 1b | ||||||
| Bauer 1994 [ | RCT | CF | 73 (36/37) | CPT | 12 d | • | • | 1b | ||||||
| Natale 1994 [ | RXO | CF | 9 | IPV | 5 d | • | • | 2b | ||||||
| Homnick 1995 [ | RCT | CF | 16 (8/8) | CPT, IPV | 180 d | • | • | • | 2b | |||||
| McIlwaine 1997 [ | RCT | CF | 36 (18/18) | CPT, PEP | 1 y | • | • | • | 1b | |||||
| Plebani 1997 [ | Uncontrolled | HIV | 8 | PEP | 1 y | • | • | 4 | ||||||
| Homnick 1998 [ | RCT | CF | 33 (16/17) | CPT, OPEP | 9 d | • | • | • | 2b | |||||
| Newhouse 1998 [ | RXO | CF | 10 | CPT, OPEP, IPV | 1x | • | • | 2b | ||||||
| Van Winden 1998 [ | RXO | CF | 22 | PEP, OPEP | 2 w | • | 1b | |||||||
| Fauroux 1999 [ | RXO | CF | 16 | FET, NIV | 1x | • | • | • | • | 1b | ||||
| Gondor 1999 [ | RCT | CF | 20 (8/12) | CPT, OPEP | 2 w | • | • | 2b | ||||||
| Williams 2000 [ | RXO | CF | 26 | CPT, ACBT | 1x | • | • | • | 2b | |||||
| McIlwaine 2001 [ | RCT | CF | 40 (20/20) | PEP, OPEP | 1 y | • | • | • | • | 2b | ||||
| Williams 2001 [ | RXO | CF | 15 | CPT, ACBT | 1x | • | • | 2b | ||||||
| Samransamruajkit 2003 [ | RCT | Asthma | 40 (20/20) | OPEP | 2 d | • | • | • | 1b | |||||
| Marks 2004 [ | RXO | CF | 10 | CPT, IPV | 1x | • | • | • | 2b | |||||
| Phillips 2004 [ | RXO | CF | 10 | HFCWO, ACBT | 2x | • | • | • | 2b | |||||
| Darbee 2005 [ | RXO | CF | 15 | HFCWO, PEP | 2x | • | • | 1b | ||||||
| Lagerkvist 2006 [ | RXO | CF | 15 | PEP, OPEP | 1x | • | • | 1b | ||||||
| Hristara-Papadopoulou 2007 [ | RXO | CF | 35 | CPT, ACBT | 1x | • | 2b | |||||||
| Indinnimeo 2007 [ | RCT | multiple | 19 (12/7) | CPT | 1 m | • | 2b | |||||||
| Tannenbaum 2007 [ | RCT | CF | 18 (9/9) | CPT | 1x | • | 2b | |||||||
| Didario 2009 [ | RCT | Asthma | 40 (20/20) | CPT | 6x in 24 h | • | • | 2b | ||||||
| Bannier 2010 [ | Uncontrolled | CF | 10 | Breathing exercises | 1x | • | • | • | 2b | |||||
| McIlwaine 2010 [ | RXO | CF | 18 | CPT, AD | 1 y | • | • | • | • | 1b | ||||
| Reix 2012 [ | RXO | CF | 32 | ACBT, exercise | 1x | • | • | • | 1b | |||||
| Abbas 2013 [ | Uncontrolled | CF | 25 | PEP/OPEP | 1x | • | 2b | |||||||
| McIlwaine 2013 [ | RCT | CF | 107 (51/56) | PEP, HFCWO | 1 y | • | • | • | 2b | |||||
| Gokdemir 2014 [ | RXO | PCD | 24 | CPT, HFCWO | 5 d | • | • | • | 2b | |||||
| Hortal 2014 [ | Uncontrolled | CF | 8 | AD, PEP | 1x | • | 4 | |||||||
| Voldby 2018 [ | Uncontrolled | CF | 10 | Exercise, PEP | 2x | • | 4 | |||||||
| Ghasempour 2019 [ | RCT | CF | 40 (20/20) | PEP | 6 d | • | • | • | 1b | |||||
| Vendrusculo 2019 [ | RXO | CF | 12 | AD, PEP | 1x | • | • | 2b | ||||||
Abbreviations: ACBT active cycle of breathing technique, ACT airway clearance technique, AD autogenic drainage, CF cystic fibrosis, CPT chest physical therapy, DE disease exacerbation parameters, EX exercise, FET forced expiration technique, HFCWO high frequency chest wall oscillation, IM imaging, IPV intrapulmonary percussive ventilation, LOE level of evidence, n number of subjects, NIV non-invasive ventilation, (O) PEP (oscillatory) positive expiratory pressure, OTH other type of measures, OX oxygenation, PCD primary ciliary dyskinesia, PFT pulmonary function test, PRO patient-reported outcome, RCT randomized clinical trial, RXO randomized crossover trial, SP expectorated sputum
Key considerations
| Outcome measure | Indications, advantages | Limitations |
|---|---|---|
| Pulmonary function | - Suitable for long-term studies. - Conventional PFT (i.e. spirometry, body plethysmography): valid measures, reference equations and extensive guidelines available. | - Inappropriate to detect acute changes related to ACTs. - Pulmonary function is measured as a single unit (‘black box’ principle). No regional abnormalities or changes can be detected. - Conventional PFT: insensitive to mild lung disease. - Age appropriate approach required. - The potential of PFT in infants and preschoolers remains unclear. |
| Expectorated sputum | - Sputum quantity gives an impression of mucus transport in short-term studies. | - Sputum quantity: inaccurate, unreliable, unsuitable for uncooperative children. |
| Oxygen measurements | - Provides information about the presence of a ventilation-perfusion mismatch. - ABG analysis is the ‘gold standard’ method to measure blood oxygenation status. - Pulse oximetry is suitable for continuous monitoring and is simple to perform. | - ABG analysis requires invasive sampling. - Pulse oximetry is too imprecise for research purposes to detect small changes. - Oxygenation as an outcome is not suitable for children with mild lung disease in stable conditions. |
| Exercise capacity | - Adequate for long-term studies focused on pulmonary rehabilitation. | - Exercise capacity cannot be measured in children <6y. - Inappropriate to evaluate short-term effects of airway clearance. - Inadequate to measure solely the effects of airway clearance. |
| Imaging | - Detailed regional information of the lungs. - Hyperpolarized MRI is sensitive to changes in ventilation distribution. - RAT technique is the most direct technique to quantify acute changes in mucus transport. | - Chest X-rays lack sufficient sensitivity. - CT imaging is associated with radiation exposure. - Subjectivity of scoring methods. - Limited availability and high cost of most techniques. |
| Disease exacerbation parameters | - Demonstrate the impact on pulmonary exacerbations, which is a direct clinical endpoint. - No complex testing material is required to achieve this information. | - Only relevant for long-term studies. |
| Patient-reported outcomes | - The inclusion of PROs promotes a patient-centered model of care. - The perception and preference of the patient will influence adherence to the therapy, which emphasizes the importance of PROs for the evaluation of ACTs. | - There are a large number of PROs available, but not all PROs are validated and therefore results should be interpreted with caution. - High risk of bias if subjects are not blinded to the therapy. |